TriangleIntismeran autogene (NCT06961006)
Intismeran autogene trial for Malignant Melanoma (NCT06961006). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable stage III or IV skin melanoma starting advanced-disease treatment. Earlier treatment around surgery is allowed if relapse occurred more than twelve months after treatment ended.
The idea: randomly add personalized intismeran autogene vaccine or placebo to pembrolizumab. The vaccine aims to direct immunity against the person's cancer; pembrolizumab blocks PD-1 immune suppression. Vaccine or placebo injections go into muscle every three weeks, with pembrolizumab infusions every six weeks. Researchers track progression-free survival.
This phase 2 study plans 160 patients. Merck sponsors five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.